Class information for:
Level 1: ESSENTIAL THROMBOCYTHEMIA//POLYCYTHEMIA VERA//MYELOFIBROSIS

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
115 4325 38.2 79%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
51 3       HEMATOLOGY//BONE MARROW TRANSPLANTATION//BLOOD 91443
2046 2             ESSENTIAL THROMBOCYTHEMIA//POLYCYTHEMIA VERA//MYELOFIBROSIS 5358
115 1                   ESSENTIAL THROMBOCYTHEMIA//POLYCYTHEMIA VERA//MYELOFIBROSIS 4325

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 ESSENTIAL THROMBOCYTHEMIA authKW 3069585 13% 79% 549
2 POLYCYTHEMIA VERA authKW 2477521 12% 70% 501
3 MYELOFIBROSIS authKW 2133121 11% 62% 484
4 MYELOPROLIFERATIVE NEOPLASMS authKW 1719689 8% 70% 348
5 JAK2V617F authKW 1061704 4% 84% 179
6 MYELOPROLIFERATIVE DISORDERS authKW 980873 6% 50% 280
7 PRIMARY MYELOFIBROSIS authKW 870512 3% 83% 149
8 ESSENTIAL THROMBOCYTHAEMIA authKW 743353 3% 82% 129
9 ANAGRELIDE authKW 608447 2% 86% 100
10 JAK2 V617F MUTATION authKW 605026 2% 85% 101

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 Hematology 179660 62% 1% 2666
2 Oncology 7067 22% 0% 964
3 Pathology 1602 6% 0% 263
4 Medicine, General & Internal 1065 9% 0% 382
5 Peripheral Vascular Diseases 593 4% 0% 181
6 Medicine, Research & Experimental 213 4% 0% 166
7 Medical Laboratory Technology 161 1% 0% 55
8 Transplantation 82 1% 0% 57
9 Cell Biology 45 4% 0% 169
10 Cell & Tissue Engineering 23 0% 0% 13

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 HEMATOL BLOOD COAGULAT 248058 1% 69% 51
2 STUDY MYELOFIBROSIS 207115 1% 65% 45
3 HEMATOL 135094 22% 2% 971
4 LEUKEMIA SERV 50216 1% 15% 47
5 CONGIUNTO MMPC 50191 0% 89% 8
6 THROMBOCYTHEMIA VERA STUDY GRP 49408 0% 100% 7
7 LEUKEMIA 47191 3% 5% 128
8 GOODHEART 44941 0% 58% 11
9 HEMATOL INTERNAL MED 43624 1% 11% 58
10 MYELOPROLIFERAT DISORDERS CONSORTIUM 43230 0% 88% 7

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 EUROPEAN JOURNAL OF HAEMATOLOGY 42040 3% 4% 151
2 BRITISH JOURNAL OF HAEMATOLOGY 41738 7% 2% 283
3 AMERICAN JOURNAL OF HEMATOLOGY 38327 4% 3% 180
4 BLOOD 26623 8% 1% 362
5 CURRENT HEMATOLOGIC MALIGNANCY REPORTS 23034 1% 10% 32
6 ANNALS OF HEMATOLOGY 22297 2% 3% 108
7 HAEMATOLOGICA 18546 2% 3% 98
8 LEUKEMIA RESEARCH 15025 3% 2% 114
9 LEUKEMIA 14210 3% 2% 124
10 LEUKEMIA & LYMPHOMA 13895 3% 2% 123

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 ESSENTIAL THROMBOCYTHEMIA 3069585 13% 79% 549 Search ESSENTIAL+THROMBOCYTHEMIA Search ESSENTIAL+THROMBOCYTHEMIA
2 POLYCYTHEMIA VERA 2477521 12% 70% 501 Search POLYCYTHEMIA+VERA Search POLYCYTHEMIA+VERA
3 MYELOFIBROSIS 2133121 11% 62% 484 Search MYELOFIBROSIS Search MYELOFIBROSIS
4 MYELOPROLIFERATIVE NEOPLASMS 1719689 8% 70% 348 Search MYELOPROLIFERATIVE+NEOPLASMS Search MYELOPROLIFERATIVE+NEOPLASMS
5 JAK2V617F 1061704 4% 84% 179 Search JAK2V617F Search JAK2V617F
6 MYELOPROLIFERATIVE DISORDERS 980873 6% 50% 280 Search MYELOPROLIFERATIVE+DISORDERS Search MYELOPROLIFERATIVE+DISORDERS
7 PRIMARY MYELOFIBROSIS 870512 3% 83% 149 Search PRIMARY+MYELOFIBROSIS Search PRIMARY+MYELOFIBROSIS
8 ESSENTIAL THROMBOCYTHAEMIA 743353 3% 82% 129 Search ESSENTIAL+THROMBOCYTHAEMIA Search ESSENTIAL+THROMBOCYTHAEMIA
9 ANAGRELIDE 608447 2% 86% 100 Search ANAGRELIDE Search ANAGRELIDE
10 JAK2 V617F MUTATION 605026 2% 85% 101 Search JAK2+V617F+MUTATION Search JAK2+V617F+MUTATION

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 TEFFERI, A , (2016) MYELOPROLIFERATIVE NEOPLASMS: A DECADE OF DISCOVERIES AND TREATMENT ADVANCES.AMERICAN JOURNAL OF HEMATOLOGY. VOL. 91. ISSUE 1. P. 50 -58 96 94% 6
2 TEFFERI, A , BARBUI, T , (2015) CME INFORMATION: POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA: 2015 UPDATE ON DIAGNOSIS, RISK-STRATIFICATION, AND MANAGEMENT.AMERICAN JOURNAL OF HEMATOLOGY. VOL. 90. ISSUE 2. P. 163 -173 83 88% 49
3 MESA, R , JAMIESON, C , BHATIA, R , DEININGER, MW , GERDS, AT , GOJO, I , GOTLIB, J , GUNDABOLU, K , HOBBS, G , KLISOVIC, RB , ET AL (2016) MYELOPROLIFERATIVE NEOPLASMS, VERSION 2.2017.JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK. VOL. 14. ISSUE 12. P. 1572 -1611 120 96% 0
4 KVASNICKA, HM , THIELE, J , (2010) PRODROMAL MYELOPROLIFERATIVE NEOPLASMS: THE 2008 WHO CLASSIFICATION.AMERICAN JOURNAL OF HEMATOLOGY. VOL. 85. ISSUE 1. P. 62-69 117 98% 39
5 VANNUCCHI, AM , GUGLIELMELLI, P , TEFFERI, A , (2009) ADVANCES IN UNDERSTANDING AND MANAGEMENT OF MYELOPROLIFERATIVE NEOPLASMS.CA-A CANCER JOURNAL FOR CLINICIANS. VOL. 59. ISSUE 3. P. 171 -191 145 73% 66
6 HASSELBALCH, HC , LARSEN, TS , RILEY, CH , JENSEN, MK , KILADJIAN, JJ , (2011) INTERFERON-ALPHA IN THE TREATMENT OF PHILADELPHIA-NEGATIVE CHRONIC MYELOPROLIFERATIVE NEOPLASMS. STATUS AND PERSPECTIVES.CURRENT DRUG TARGETS. VOL. 12. ISSUE 3. P. 392 -419 153 73% 8
7 BARBUI, T , THIELE, J , GISSLINGER, H , FINAZZI, G , VANNUCCHI, AM , TEFFERI, A , (2016) THE 2016 REVISION OF WHO CLASSIFICATION OF MYELOPROLIFERATIVE NEOPLASMS: CLINICAL AND MOLECULAR ADVANCES.BLOOD REVIEWS. VOL. 30. ISSUE 6. P. 453 -459 84 98% 3
8 BOSE, P , VERSTOVSEK, S , (2016) MYELOFIBROSIS: AN UPDATE ON DRUG THERAPY IN 2016.EXPERT OPINION ON PHARMACOTHERAPY. VOL. 17. ISSUE 18. P. 2375 -2389 101 96% 0
9 CERVANTES, F , PASSAMONTI, F , BAROSI, G , (2008) LIFE EXPECTANCY AND PROGNOSTIC FACTORS IN THE CLASSIC BCR/ABL-NEGATIVE MYELOPROLIFERATIVE DISORDERS.LEUKEMIA. VOL. 22. ISSUE 5. P. 905 -914 96 99% 96
10 BRYAN, JC , VERSTOVSEK, S , (2016) OVERCOMING TREATMENT CHALLENGES IN MYELOFIBROSIS AND POLYCYTHEMIA VERA: THE ROLE OF RUXOLITINIB.CANCER CHEMOTHERAPY AND PHARMACOLOGY. VOL. 77. ISSUE 6. P. 1125 -1142 77 96% 4

Classes with closest relation at Level 1


Rank Class id link
1 22843 CHRONIC NEUTROPHILIC LEUKEMIA//CHRONIC NEUTROPHILIC LEUKAEMIA//COLONY STIMULATING FACTOR 3 RECEPTOR MUTATION
2 29549 ERYTHROMELALGIA//ERYTHERMALGIA//SECONDARY ERYTHROMELALGIA
3 28077 THROMBOCYTOSIS//CAROTID ARTERY THROMBUS//FLOATING PLAQUE
4 13676 TOFACITINIB//JAK3//JANUS KINASE
5 34490 HIGH DOSE METHYLPREDNISOLONE//APOPTOSIS OF LYMPHOBLASTIC LEUKEMIC CELLS//CHANGHAI HOSP HEMATOL
6 16788 EXTRAMEDULLARY HEMATOPOIESIS//EXTRAMEDULLARY HAEMATOPOIESIS//HEMATOPOIESIS EXTRAMEDULLARY
7 27397 DEL20Q//IDER20Q//TETRASOMY 8
8 22559 HYDROXYUREA//GENET HUMAN THER Y//AV HALTS
9 25899 M27 BETA//REPEATED BETA RADIATION//CLONALITY
10 25249 PULSE DYE DENSITOMETRY//PULSE SPECTROPHOTOMETRY//BLOOD VOLUME DETERMINATION

Go to start page